ELDN NASDAQ
Credit Risk of going bust: lower than 81% of companies Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Eledon Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $467K against a stock market value of $179.6M.
Distance to default 9.93 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $234K (short-term plus half of long-term), stock volatility 65.3%; Altman Z'' -10.89. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Irvine, CA 92612
US
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Gros David-Alexandre | A-Award | 354,454 | — | 2026-07-31 |
| Gros David-Alexandre | F-InKind | 194,791 | $3.38 | 2026-07-31 |
| Perrin Steven | A-Award | 152,353 | — | 2026-07-31 |
| Perrin Steven | F-InKind | 72,138 | $3.38 | 2026-07-31 |
| McBride John S. | M-Exempt | 3,430 | — | 2026-01-10 |